Compare RDNW & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDNW | DERM |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.0M | 190.3M |
| IPO Year | 2014 | 2021 |
| Metric | RDNW | DERM |
|---|---|---|
| Price | $5.32 | $4.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.50 | ★ $13.75 |
| AVG Volume (30 Days) | 46.0K | ★ 193.9K |
| Earning Date | 11-10-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.84 | 34.72 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $1,793,369,000.00 | $61,858,000.00 |
| Revenue This Year | $3.88 | $25.29 |
| Revenue Next Year | $5.55 | $50.00 |
| P/E Ratio | $89.00 | ★ N/A |
| Revenue Growth | ★ 91.10 | 10.20 |
| 52 Week Low | $4.08 | $4.31 |
| 52 Week High | $8.55 | $9.56 |
| Indicator | RDNW | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 50.97 | 36.54 |
| Support Level | $4.64 | $4.31 |
| Resistance Level | $7.14 | $5.50 |
| Average True Range (ATR) | 0.38 | 0.33 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 60.33 | 18.50 |
RideNow Group Inc operates solely as a powersports dealership group. Its offerings include new and pre-owned vehicles such as motorcycles, all-terrain vehicles (ATVs), side-by-side vehicles (SXS), and personal watercraft (PWC). It also sells parts, apparel, and accessories, and provides financing, insurance, and aftermarket products, along with repair and maintenance services. The majority of the company's revenue is derived from powersports vehicle sales, and the rest from parts, service and accessories/merchandise, and finance and insurance products.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.